DekaBank Deutsche Girozentrale Boosts Position in Radius Health, Inc. (RDUS)
DekaBank Deutsche Girozentrale raised its stake in Radius Health, Inc. (NASDAQ:RDUS) by 45.9% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 95,300 shares of the biopharmaceutical company’s stock after purchasing an additional 30,000 shares during the quarter. DekaBank Deutsche Girozentrale owned 0.21% of Radius Health worth $3,472,000 as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors also recently modified their holdings of RDUS. BlackRock Inc. raised its stake in shares of Radius Health by 98,245.6% in the first quarter. BlackRock Inc. now owns 2,630,745 shares of the biopharmaceutical company’s stock worth $101,679,000 after purchasing an additional 2,628,070 shares during the last quarter. Farallon Capital Management LLC raised its stake in shares of Radius Health by 18.3% in the second quarter. Farallon Capital Management LLC now owns 3,686,300 shares of the biopharmaceutical company’s stock worth $166,731,000 after purchasing an additional 569,300 shares during the last quarter. TimesSquare Capital Management LLC purchased a new stake in shares of Radius Health in the second quarter worth approximately $25,589,000. BB Biotech AG raised its stake in shares of Radius Health by 11.0% in the second quarter. BB Biotech AG now owns 5,038,799 shares of the biopharmaceutical company’s stock worth $227,905,000 after purchasing an additional 498,400 shares during the last quarter. Finally, RA Capital Management LLC purchased a new stake in shares of Radius Health in the second quarter worth approximately $22,486,000.
Several brokerages have recently commented on RDUS. Cantor Fitzgerald reissued a “buy” rating and issued a $58.00 price objective on shares of Radius Health in a research note on Friday, November 3rd. Jefferies Group LLC lowered their price objective on Radius Health from $38.00 to $31.00 and set a “hold” rating for the company in a research note on Friday, November 3rd. Goldman Sachs Group, Inc. (The) reissued a “neutral” rating and issued a $45.00 price objective on shares of Radius Health in a research note on Friday, October 6th. Zacks Investment Research downgraded Radius Health from a “hold” rating to a “sell” rating in a research note on Wednesday, October 4th. Finally, Maxim Group reissued a “positive” rating on shares of Radius Health in a research note on Friday, September 29th. They noted that the move was a valuation call. Two analysts have rated the stock with a sell rating, four have issued a hold rating and five have given a buy rating to the company’s stock. Radius Health has a consensus rating of “Hold” and an average price target of $51.00.
Shares of Radius Health, Inc. (NASDAQ RDUS) opened at $27.42 on Tuesday. The company has a debt-to-equity ratio of 0.53, a quick ratio of 12.79 and a current ratio of 12.87. Radius Health, Inc. has a 52-week low of $24.66 and a 52-week high of $55.30.
Radius Health (NASDAQ:RDUS) last issued its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.31) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.28) by ($0.03). The company had revenue of $13.50 million during the quarter, compared to the consensus estimate of $6.90 million. During the same period last year, the firm earned ($1.07) earnings per share. research analysts predict that Radius Health, Inc. will post -5.4 earnings per share for the current fiscal year.
In other news, insider Jesper Hoiland acquired 6,100 shares of Radius Health stock in a transaction on Friday, September 15th. The stock was acquired at an average cost of $32.72 per share, with a total value of $199,592.00. Following the completion of the acquisition, the insider now owns 6,100 shares in the company, valued at $199,592. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Jose Carmona acquired 3,000 shares of Radius Health stock in a transaction on Thursday, September 14th. The shares were purchased at an average cost of $32.83 per share, with a total value of $98,490.00. Following the completion of the acquisition, the chief financial officer now owns 3,000 shares of the company’s stock, valued at approximately $98,490. The disclosure for this purchase can be found here. Over the last three months, insiders have acquired 417,678 shares of company stock valued at $13,583,998. 15.00% of the stock is owned by corporate insiders.
ILLEGAL ACTIVITY WARNING: “DekaBank Deutsche Girozentrale Boosts Position in Radius Health, Inc. (RDUS)” was originally published by Daily Political and is the property of of Daily Political. If you are reading this piece on another site, it was copied illegally and republished in violation of U.S. and international copyright laws. The correct version of this piece can be read at https://www.dailypolitical.com/2017/11/21/dekabank-deutsche-girozentrale-boosts-position-in-radius-health-inc-rdus.html.
Radius Health Profile
Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.
Want to see what other hedge funds are holding RDUS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Radius Health, Inc. (NASDAQ:RDUS).
Receive News & Ratings for Radius Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.